AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABCL AbCellera Biologics

马丁-路德-金纪念日休市 01-16 16:00:00 EST

4.12

-0.06

-1.44%

盘后4.21

+0.09+2.12%

19:59 EST

最高4.38	最低4.09	成交量538.98万
今开4.19	昨收4.18	日振幅6.94%
总市值12.33亿	流通市值8.35亿	总股本2.99亿
成交额2,282万	换手率2.66%	流通股本2.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":4.12,"timestamp":1768597200000,"preClose":4.18,"halted":0,"volume":5389833,"hourTrading":{"tag":"盘后","latestPrice":4.2072,"preClose":4.12,"latestTime":"19:59 EST","volume":21739,"amount":90194.9688,"timestamp":1768611581791,"change":0.0872,"changeRate":0.021165,"amplitude":0.038835},"delay":0,"changeRate":-0.01435406698564584,"floatShares":202749853,"shares":299335048,"eps":-0.576766,"marketStatus":"马丁-路德-金纪念日休市","change":-0.06,"latestTime":"01-16 16:00:00 EST","open":4.19,"high":4.38,"low":4.09,"amount":22822458.2279655,"amplitude":0.069378,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.576766,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":4.18,"preHourTrading":{"tag":"盘前","latestPrice":4.1917,"preClose":4.18,"latestTime":"09:25 EST","volume":11560,"amount":48551.97688,"timestamp":1768573546296,"change":0.0117,"changeRate":0.002799,"amplitude":0.009569},"postHourTrading":{"tag":"盘后","latestPrice":4.2072,"preClose":4.12,"latestTime":"19:59 EST","volume":21739,"amount":90194.9688,"timestamp":1768611581791,"change":0.0872,"changeRate":0.021165,"amplitude":0.038835},"volumeRatio":0.9635727466575401,"impliedVol":0.9787,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2603668067","title":"Abcellera Biologics Inc.盘中异动 早盘大幅拉升5.15%报4.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603668067?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:31","pubTimestamp":1768228298,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时31分，Abcellera Biologics Inc.股票出现异动，股价急速拉升5.15%。截至发稿，该股报4.60美元/股，成交量46.0216万股，换手率0.15%，振幅2.71%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223138a71203e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223138a71203e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"1146146378","title":"AbCellera宣布其治疗更年期血管舒缩症状药物Abcl635的1/2期临床试验进入第二阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1146146378","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146146378?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:01","pubTimestamp":1768226505,"startTime":"0","endTime":"0","summary":"AbCellera Biologics宣布，其针对更年期血管舒缩症状的候选药物Abcl635，在1/2期临床试验中已完成第一阶段，并已启动第二阶段，首批患者已接受给药。这一进展标志着该药物研发进入新阶段，旨在评估Abcl635在更广泛患者群体中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"1189821615","title":"异动解读 | 分析师维持买入评级，AbCellera Biologics盘后大涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189821615","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189821615?lang=zh_cn&edition=full","pubTime":"2025-11-08 08:02","pubTimestamp":1762560161,"startTime":"0","endTime":"0","summary":"生物技术公司AbCellera Biologics在周五盘后交易中股价大涨5.37%，引发市场关注。消息面上，斯迪富分析师Stephen Willey在最新的研究报告中维持了对AbCellera Biologics的买入评级，目标价保持在7美元不变。这一积极的分析师评级可能是推动公司股价上涨的主要因素。值得注意的是，根据金融数据提供商TipRanks的统计，Stephen Willey分析师在过去一年的总体胜率为43.8%，平均回报率达6.8%。这一数据为投资者提供了额外的参考信息，可能进一步增强了市场对AbCellera Biologics前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"gpt_icon":0},{"id":"1159304378","title":"异动解读 | AbCellera Biologics盘后大涨5.37%，斯迪富维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1159304378","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159304378?lang=zh_cn&edition=full","pubTime":"2025-11-08 08:02","pubTimestamp":1762560160,"startTime":"0","endTime":"0","summary":"周五盘后交易中，AbCellera Biologics股价大涨5.37%，引起投资者关注。这一显著涨幅可能与分析师的最新评级有关。据报道，斯迪富分析师Stephen Willey维持对AbCellera Biologics的买入评级，目标价保持在7美元。这一积极的评级可能提振了投资者信心，推动了股价在盘后交易中的上涨。值得注意的是，根据TipRanks的数据，Stephen Willey分析师近一年的总胜率为43.8%，总平均回报率为6.8%。投资者在做出投资决策时，仍需谨慎考虑多方面因素，全面评估公司基本面和市场风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"gpt_icon":0},{"id":"1180602153","title":"异动解读 | 分析师下调评级，AbCellera Biologics盘中暴跌超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180602153","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180602153?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:44","pubTimestamp":1762526643,"startTime":"0","endTime":"0","summary":"周五盘中，生物技术公司AbCellera Biologics股价出现暴跌，跌幅高达20.31%，引发市场广泛关注。这一大幅下跌主要源于知名投资银行Leerink Partners对该公司评级的下调。据悉，Leerink Partners将AbCellera Biologics的投资评级从\"跑赢大盘\"下调至\"市场表现\"，同时将目标价从5美元下调至4美元。AbCellera Biologics是一家专注于抗体发现和开发的生物技术公司。此次评级下调可能暗示投资者对公司的业务前景和市场竞争力产生了担忧。市场将继续关注AbCellera Biologics的后续表现，以及公司如何应对这一挑战。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"gpt_icon":0},{"id":"2581552832","title":"Abcellera Biologics Inc.盘中异动 股价大跌19.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581552832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581552832?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:32","pubTimestamp":1762525974,"startTime":"0","endTime":"0","summary":"北京时间2025年11月07日22时32分，Abcellera Biologics Inc.股票出现波动，股价急速下跌19.66%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.44%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。消息层面，截至22时32分，《TD Cowen维持AbCellera Biologics买入评级》资讯为影响Abcellera Biologics Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107223255a49089fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107223255a49089fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","ABCL","BK4121"],"gpt_icon":0},{"id":"1173083499","title":"异动解读 | 分析师下调评级，AbCellera Biologics盘前大跌13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173083499","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173083499?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:38","pubTimestamp":1762519102,"startTime":"0","endTime":"0","summary":"周五盘前，生物技术公司AbCellera Biologics股价出现大幅下跌，跌幅高达13%，引起市场广泛关注。造成股价暴跌的主要原因是知名投资银行Leerink Partners对AbCellera Biologics的投资评级做出了下调。这一评级调整反映了分析师对公司未来表现的预期降低。AbCellera Biologics是一家专注于抗体发现和开发的生物技术公司。此次评级下调可能暗示投资者对公司的业务前景和市场竞争力产生了担忧。面对如此大幅度的股价下跌，投资者需密切关注公司未来的业务发展和市场表现，以评估其长期投资价值。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"gpt_icon":0},{"id":"1175896075","title":"AbCellera Biologics Inc：Leerink Partners下调评级至市场表现，从跑赢大盘下调；目标价从5美元降至4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175896075","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175896075?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518977,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc：Leerink Partners下调评级至市场表现，从跑赢大盘下调；目标价从5美元降至4美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2558525665","title":"Abcellera Biologics Inc.盘中异动 早盘快速上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558525665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558525665?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:32","pubTimestamp":1754919144,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时32分，Abcellera Biologics Inc.股票出现异动，股价急速拉升5.18%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.46%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。凭借集成的AbCellera平台，公司的专家能够快速搜索广泛的多样化抗体，挑选出有效且可开发的先导药物，为合作伙伴的持久成功奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213224a6dfb883&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213224a6dfb883&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"1129648588","title":"异动解读 | AbCellera Biologics盘中大跌5.19%，尽管Q2业绩显示收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1129648588","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129648588?lang=zh_cn&edition=full","pubTime":"2025-08-08 22:09","pubTimestamp":1754662148,"startTime":"0","endTime":"0","summary":"生物技术公司AbCellera Biologics今日盘中大跌5.19%，引发投资者关注。该公司最近公布了2025年第二季度财报，虽然收入大幅增长，但市场反应似乎并不乐观。根据公司财报，AbCellera第二季度收入达到1700万美元，相比去年同期的700万美元有显著增长。尽管财务状况稳健，但投资者似乎对公司面临的风险和挑战存有顾虑。AbCellera已成功从平台公司转型为临床阶段公司，启动了ABCL-635和ABCL-575的临床试验，并将ABCL-688推进至IND支持研究阶段。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ABCL"],"gpt_icon":0},{"id":"1182842110","title":"AbCellera Biologics 2025年第二季度业绩会总结及问答精华：临床进展与财务稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=1182842110","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182842110?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:33","pubTimestamp":1754659984,"startTime":"0","endTime":"0","summary":"公司管理层表示，AbCellera Biologics 已成功从平台公司转型为临床阶段公司，获得了加拿大卫生部的授权，启动了ABCL-635和ABCL-575的临床试验。公司计划在2025年底前完成GMP设施建设，并继续推进临床和预临床项目。净亏损为3500万美元，较去年同期减少200万美元。预计ABCL-635的主要科学风险在于目标结合的充分性，安全性和有效性数据将在2026年中期提供。AbCellera Biologics在2025年第二季度取得了显著进展，成功从平台公司转型为临床阶段公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"gpt_icon":0},{"id":"2557269527","title":"Abcellera Biologics Inc.盘中异动 股价大涨16.23%报4.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557269527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557269527?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:31","pubTimestamp":1754659903,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时31分，Abcellera Biologics Inc.股票出现波动，股价快速上涨16.23%。截至发稿，该股报4.93美元/股，成交量143.873万股，换手率0.48%，振幅5.19%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213143a47d5a8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213143a47d5a8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2557309830","title":"Abcellera Biologics Inc.盘中异动 急速下跌5.05%报4.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557309830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557309830?lang=zh_cn&edition=full","pubTime":"2025-08-07 00:48","pubTimestamp":1754498925,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日00时48分，Abcellera Biologics Inc.股票出现异动，股价大幅跳水5.05%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。凭借集成的AbCellera平台，公司的专家能够快速搜索广泛的多样化抗体，挑选出有效且可开发的先导药物，为合作伙伴的持久成功奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807004846a6d6fbe4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807004846a6d6fbe4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2555050462","title":"Abcellera Biologics Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555050462","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555050462?lang=zh_cn&edition=full","pubTime":"2025-07-29 23:26","pubTimestamp":1753802778,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日23时26分，Abcellera Biologics Inc.股票出现波动，股价快速下挫5.08%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Abcellera Biologics Inc.公司简介：AbCellera Biologics Inc 是一家专门设计用于克服传统发现障碍的抗体发现和开发引擎，能够以更高的精确度和速度找到最佳临床候选药物，更快地用于临床和患者。凭借集成的AbCellera平台，公司的专家能够快速搜索广泛的多样化抗体，挑选出有效且可开发的先导药物，为合作伙伴的持久成功奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072923261894c1d2c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072923261894c1d2c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2516608444","title":"Abcellera Biologics Inc.盘中异动 早盘快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516608444?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:20","pubTimestamp":1741101638,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时20分，Abcellera Biologics Inc.股票出现异动，股价急速下跌5.03%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.42%。Abcellera Biologics Inc.公司简介：AbCelera Biologics Inc 是一家抗体发现和开发引擎公司，专门设计用于解决传统发现的障碍，以更高的精度和速度找到最佳的临床候选药物，更快地到达诊所和患者面前。借助综合AbCelera平台，公司的专家可以搜索各种不同的抗体，从而快速筛选出有效和可开发的先导药物，帮助合作伙伴取得持久的成功。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232039963952ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232039963952ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2516320356","title":"Abcellera Biologics Inc.盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516320356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516320356?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:57","pubTimestamp":1741013862,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时57分，Abcellera Biologics Inc.股票出现波动，股价急速下跌5.19%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Abcellera Biologics Inc.公司简介：AbCelera Biologics Inc 是一家抗体发现和开发引擎公司，专门设计用于解决传统发现的障碍，以更高的精度和速度找到最佳的临床候选药物，更快地到达诊所和患者面前。AbCelera利用专有硬件、软件和工具以及最新的数据科学，作为战略合作伙伴运营，并帮助更快地为任何项目开发优化的解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257429637b36c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032257429637b36c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2514320181","title":"Abcellera Biologics Inc.盘中异动 大幅跳水11.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320181","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514320181?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753085,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Abcellera Biologics Inc.股票出现波动，股价急速下跌11.22%。Abcellera Biologics Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Abcellera Biologics Inc.公司简介：AbCelera Biologics Inc 是一家抗体发现和开发引擎公司，专门设计用于解决传统发现的障碍，以更高的精度和速度找到最佳的临床候选药物，更快地到达诊所和患者面前。AbCelera利用专有硬件、软件和工具以及最新的数据科学，作为战略合作伙伴运营，并帮助更快地为任何项目开发优化的解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223125abe0ea26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223125abe0ea26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2514327513","title":"Stifel：维持AbCellera Biologics(ABCL.US)评级，由买入调整至买入评级, 目标价由12.00美元调整至10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514327513","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514327513?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:05","pubTimestamp":1740751541,"startTime":"0","endTime":"0","summary":"Stifel：维持AbCellera Biologics(ABCL.US)评级，由买入调整至买入评级, 目标价由12.00美元调整至10.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28220548466907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ABCL"],"gpt_icon":0},{"id":"1111722921","title":"AbCellera Biologics 第四季度每股收益优于预期，销售额未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111722921","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111722921?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:52","pubTimestamp":1740693140,"startTime":"0","endTime":"0","summary":"AbCellera Biologics报告季度每股亏损为$-0.12，优于分析师普遍预期的$-0.15，同比增长20%。公司季度销售额为510万美元，不及分析师普遍预期的758万美元，低32.71%。与去年同期的销售额918万美元相比下降了44.44%。以上内容来自Benzinga Earnings专栏，原文如下：$AbCellera Biologics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 20 percent. This is a 25 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $5.10 million which missed the analyst consensus estimate of $7.58 million by 32.71 pe","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AbCellera Biologics 第四季度每股收益优于预期，销售额未达预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.0572},{"period":"1month","weight":0.2299},{"period":"3month","weight":-0.263},{"period":"6month","weight":-0.0804},{"period":"1year","weight":0.4014},{"period":"ytd","weight":0.2047}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AbCellera Biologics Inc.于2012年11月8日根据不列颠哥伦比亚省商业公司法注册成立并开始经营活动。该公司从事的业务是在其医学研究和开发中综合运用多种复杂技术，以更快、更廉价、更有效地发掘抗体药物。自成立以来，公司一直致力于研发活动，以支持其目前的合作伙伴项目和未来的平台开发工作。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.02709},{"month":2,"riseRate":0,"avgChangeRate":-0.143182},{"month":3,"riseRate":0.2,"avgChangeRate":-0.064544},{"month":4,"riseRate":0.2,"avgChangeRate":-0.104908},{"month":5,"riseRate":0.6,"avgChangeRate":-0.032152},{"month":6,"riseRate":0.4,"avgChangeRate":0.119513},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AbCellera Biologics(ABCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AbCellera Biologics(ABCL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}